International Journal of Environmental Sciences
ISSN: 2229-7359
Vol. 11 No. 23s, 2025
https://www.theaspd.com/ijes.php

Hyphenated Techniques In Debasement Profiling Of Efavirenz: A Survey Of LC-MS, NMR, And HPLC Applications

Rajesh Madhukar Meshram[1*], Rajesh Gour[2]
[1]Research Scholar, LNCT University, Bhopal India, rajeshmeshram.1986@rediffmail.com
[2]Associate Professor, NCT University, Bhopal India, rmlumina@gmail.com

Abstract:
Getting contaminants right-from identification to assessment-is essential for drug quality and safety. Even tiny amounts can dramatically affect a medicine's effectiveness and carry serious risks, including toxicity and possible carcinogenic effects. Contaminant profiling means identifying, characterizing, and measuring pollutants at every stage of drug development. Advanced analytical methods-like liquid chromatography and mass spectrometry-are essential for accurate detection and quantification. Regulatory guidelines lay out how to spot and manage contaminants to boost drug safety. Techniques such as crystallization and chromatography play a key role in purifying products and removing harmful contaminants. Understanding where contaminants come from and how they travel is critical for building effective control measures. Ongoing research in advanced analytical methods, together with strict regulatory compliance, is vital for keeping pharmaceutical products safe and effective.
Keywords: *pharmaceutical pollutants, contamination profiling, regulatory compliance, chromatography, administrative procedures, crystallization.*

INTRODUCTION

Significance of impurity profiling: Impurity profiling is a vital aspect of pharmaceutical quality control, ensuring drug safety and efficacy by detecting, identifying, and quantifying unwanted chemical substances present in formulations. These impurities can arise during manufacturing, from degradation in storage, or through interactions between components. Even trace amounts may lead to serious health risks such as toxicity, carcinogenicity, or teratogenicity. The process involves a thorough understanding of the drug's synthetic routes and degradation pathways, combined with advanced analytical techniques-most commonly liquid chromatography with mass spectrometry. International guidelines, particularly those from the ICH, provide standardized approaches for impurity control and regulatory compliance. Ultimately, impurity profiling is not just an analytical requirement but an essential part of risk assessment and quality assurance across the entire drug development lifecycle.[1-9]

Once impurities are identified, we characterize them by their chemical structure, their physicochemical properties, and any potential toxicity.In the later stages of drug development, the focus shifts from solving issues to prioritizing speed, durability, and reliability as we validate the manufacturing processes.[10] Impurity characterization extends beyond mere identification and quantification; it also encompasses evaluating how they may affect the quality of the product and the safety of the patients. Toxicological studies are conducted to evaluate the potential adverse effects of impurities, and acceptable limits are established based on safety thresholds. If an impurity exceeds the established threshold, steps must be taken to reduce its levels through process optimization or purification techniques. Crystallization is a common unit operation to control mutagenic impurities, relying on impurity purge mechanisms to reject impurities into the liquid phase.[11] The importance of employing orthogonal analytical techniques cannot be overstated, as different methods offer complementary information and can enhance the robustness of impurity profiling studies. Impurities can come from different sources, so knowing where they come from is essential for controlling them effectively.

The implications of impurity profiling extend beyond regulatory compliance, influencing various aspects of pharmaceutical development, manufacturing, and quality control. Early phase material for toxicology studies is often prepared from the same batch as the material used for Phase 1 clinical investigations.[12]

Identifying and managing impurities during the early stages of drug development can help companies prevent expensive setbacks and potential safety concerns in the future.

EFAVIRENZ OVERVIEW: Efavirenz, A non-nucleoside reverse transcriptase inhibitor has become a crucial component in treating HIV type 1 infection, serving as a key element in worldwide highly active antiretroviral therapy regimens.[13] Efavirenz is a crucial part of HIV treatment as it works by blocking the reverse transcriptase enzyme, which is necessary for the virus to replicate. This action helps lower the amount of virus in infected individuals and enhances their immune system function.[14] The widespread use of efavirenz is underpinned by its efficacy, relatively convenient once-daily dosing, and affordable cost, particularly in resource-limited settings where access to newer antiretroviral agents may be restricted.[15] Most patients were initiated on a regimen that included efavirenz, tenofovir disoproxil fumarate, and emtricitabine.[16]

Efavirenz, like other antiretrovirals, poses challenges such as side effects and drug resistance, which must be addressed in treatment planning. Combination therapy now emphasizes safety, tolerability, and long-term effectiveness. A thorough understanding of efavirenz—its action, pharmacokinetics, interactions, and toxicity management—is essential for HIV care. It works by non-competitively inhibiting HIV-1 reverse transcriptase, blocking viral replication and reducing viral load. The drug has high oral bioavailability, is metabolized mainly by CYP2B6, and shows wide variability in patient plasma levels, making drug monitoring useful. Clinical trials confirm its potency and ability to maintain viral suppression. However, efavirenz is linked to CNS effects (e.g., insomnia, dizziness, psychiatric issues), metabolic disturbances (dyslipidemia, lipodystrophy), and resistance—often from the K103N mutation. Mitigation strategies include adherence support, resistance testing, and switching to alternatives when needed. Its role is now gradually being redefined as newer, safer, and more effective agents emerge.[17-21]

IMPURITY PROFILING TECHNIQUES:

LCMS (Liquid Chromatography-Mass Spectrometry): LCMS is used to identify and control impurities in pharmaceuticals, which can induce adverse effects and compromise medicine safety. Impurities can have carcinogenic, toxic, or teratogenic effects, necessitating stringent control. Consequently, regulatory bodies mandate the process of identifying and measuring impurities exceeding specified thresholds.[1,6] Impurity profiling, which meticulously describes both impurities found in drug products that are known and unknown, has gained prominence in pharmacopeias, with the ICH guidelines for analyzing impurities in new drug substances.[2] LCMS is recognized as a crucial analytical method for identifying trace elements, such as impurities and degraded substances, in both drug compounds and products.[22]

The combination of liquid chromatography and mass spectrometry has greatly advanced the way impurities in pharmaceutical drugs such as Efavirenz are detected and identified.[23] The flexibility of LC-MS allows for the sorting of intricate combinations according to their physical and chemical characteristics, followed by mass spectrometric analysis that provides structural information, facilitating the identification of even trace amounts of impurities.[24]

High-performance liquid chromatography (HPLC) when attached with mass spectrometry fulfills the stringent requirements for quality control, offering a wide range of technical options and applications.[25] Ultra-performance liquid chromatography has revolutionized liquid chromatography, enabling efficient analysis of complex samples. LC-MS is a powerful tool for impurity analysis, offering enhanced sensitivity, specificity, and detection capabilities. It's widely used to detect impurities in pharmaceuticals and food contaminants. LC-MS integrates separation and detection, making it invaluable for complex matrices. High- resolution mass spectrometry accurately measures mass, helping identify unknown impurities. LC-MS detects impurities at low concentrations, making it a crucial tool in pharmaceutical analysis. It's used to identify and quantify impurities in pharmaceuticals like Efavirenz.[26-32]

The pump is used to move the mobile phase.[33] The HPLC technique is suitable for analyzing a variety of substances including carbohydrates, lipids, vitamins, additives, synthetic colorings, natural pigments, contaminants, and amino acids.[34]

Ensuring the quality and safety of Efavirenz relies on the strength and dependability of LC-MS techniques, making method validation essential to prove specificity, linearity, accuracy, precision, and sensitivity. The determination of solubility is done by weighing the compound and placing it in test tubes with solvent,

shaking until the solute dissolves with vigorous agitation. Moreover, the utilization of internal standards can further improve accuracy and precision.[35] Using the right cleanup methods, like solid phase extraction, can greatly lower the presence of interfering substances and enhance the signal-to-noise ratio. This allows for mass spectral confirmation and lowers the quantification limits.[36] The mixture, extracted alongside the substances being analyzed, has the potential to change the signal response. This can lead to either suppression or enhancement, resulting in compromised accuracy, linearity, and reproducibility in analytical results.[37]

1H NMR (Proton Nuclear Magnetic Resonance): 1H NMR spectroscopy stands as a cornerstone analytical technique in the realm of chemistry, providing extraordinary perspectives on the composition and movement of molecules, and serving a crucial function in discovering and describing contaminants in intricate chemical combinations.[38,39] The method relies on the basic principle that atomic nuclei containing an odd number of protons or neutrons have a magnetic moment, making them sensitive to an external magnetic field.[40] When a sample is placed within a magnetic field, the nuclei within it align themselves in either alignment with or in opposition to the field, resulting in the formation of different energy levels.[41] Upon irradiation with radiofrequency energy, transitions between these energy levels occur, generating a spectrum that offers extensive details regarding the chemical surroundings of each proton within the molecule.[42]

The power of 1H NMR spectroscopy in impurity analysis stems from its ability to resolve individual signals corresponding to different protons within a molecule, with the position of each signal, known as the chemical shift, having a high level of sensitivity to the electronic conditions surrounding the proton.[43] Electronegative atoms or groups in close proximity to a proton deshield it, causing its signal to shift downfield to higher chemical shift values, while electron-donating groups shield the proton, resulting in an upfield shift . Furthermore, the amount of integration for each signal is dependent on the number of protons it corresponds to, giving precise details about the ratio of various elements in a mixture. The multiplicity of a signal, arising from spin-spin coupling between neighboring protons, further elucidates the connectivity and spatial arrangement of atoms within the molecule. By meticulously analyzing the chemical shifts, integrations, and multiplicities of signals in a 1H NMR spectrum, chemists can piece together the structural puzzle of unknown impurities, even when present in trace amounts.[44]

1H NMR spectroscopy is valuable for impurity analysis in pharmaceuticals, environmental science, and materials science. It identifies and quantifies impurities, ensuring product safety and effectiveness. Advanced NMR techniques like COSY, HSQC, and HMBC provide detailed structural information. Quantitative NMR (qHNMR) accurately determines component concentrations. NMR-based metabolomics compares chemical differences. Computational chemistry and spectral databases enhance impurity analysis. Low-field NMR spectrometers offer a cost-effective alternative for forensic analysis. NMR's non- destructive nature allows sample recovery and further characterization. Minimal sample prep enables quick and effective analysis.[45-50] Although traditional methods such as thin-layer chromatography, liquid chromatography, gas chromatography, and capillary electrophoresis combined with mass spectrometry are commonly employed to detect, measure, and analyze compounds from plant materials and other origins, NMR presents an alternative method that can offer distinctive perspectives on the composition and behavior of impurities.[51] By integrating NMR data with information obtained from other analytical techniques, such as mass spectrometry.[52] A more complete and accurate picture of the impurity profile can be obtained. Parameters for determining the structure, such as precise mass, patterns of fragmentation in MS/MS, and NMR spectra, can be integrated into a unified cheminformatics analysis tool to precisely identify unidentified metabolites in untargeted research.[53] The specificity of mass spectrometry is suited for examining complex molecules present in agriculture, atmospheric chemistry, biomedicine, food, forensics, and geochemistry.[54] Chemometrics can be used with mass spectrometry, chromatographic, electrochemical, and thermal methods to analyze data.[30] The continuous advancement in NMR technology and software is constantly expanding the limits of impurity analysis.

HPLC (High-Performance Liquid Chromatography): It is considered a crucial method of analysis that is extensively used for its capability to isolate, detect, and measure individual substances in complicated mixtures.[34] HPLC's versatility stems from its applicability to a broad spectrum of compounds,

encompassing pharmaceuticals, natural products, polymers, and various chemical entities, provided they exhibit solubility in a suitable liquid mobile phase.[55] The fundamental principle underpinning HPLC involves the partitioning of analytes between a stationary phase, typically a solid material packed within a column, and a liquid mobile phase that carries the sample through the column.[56] The differential affinity of analytes for the stationary and mobile phases leads to their separation, as compounds with a stronger affinity for the stationary phase elute later than those with a greater affinity for the mobile phase.[57] The technique's widespread adoption is further propelled by its adaptability to diverse detection methods, including UV- visible absorption, fluorescence, mass spectrometry, and refractive index detection, allowing for the sensitive and selective detection of a wide array of analytes.[32]

The ongoing evolution of HPLC encompasses advancements in column technology, instrumentation, and data processing, continually enhancing its performance and expanding its application scope. The current trends in HPLC involve the use of sub-2 μm particle size columns, which enable ultra-high-pressure liquid chromatography separations. Porous-shell particle packed columns are also being utilized to achieve high- efficiency separations with lower column back-pressures. [29] These innovative column technologies translate to improved resolution, enhanced sensitivity, and accelerated analysis times, catering to the increasing demands for high-throughput analysis in diverse fields.[26] Moreover, the combination of HPLC and mass spectrometry has transformed analytical possibilities by allowing for the identification and measurement of minute amounts of substances in intricate mixtures. Most of the improvements in the speed of separation have been linked to the advancements in column technology and instrumentation.[58] Using columns filled with sub-2 μm particles is a common method to reduce analysis time and improve resolution in ultra-high-pressure liquid chromatography.[59]

Sample preparation, honestly, it's the backbone of any decent HPLC analysis. If this step goes sideways, accuracy and reliability? Out the window. Effective sample prep is all about getting rid of unwanted matrix effects, concentrating your analytes, and tossing aside any interfering substances that could mess with your separation or detection. There's a whole toolkit for this—liquid-liquid extraction, solid-phase extraction, protein precipitation—all tailored to different sample types and analyte quirks. HPLC itself is ridiculously versatile. It's everywhere: pharmaceutical analysis, environmental monitoring, clinical diagnostics—you name it. The secret sauce is picking the right stationary phase and dialing in your mobile phase composition; get this wrong, and you're done before you start. Different HPLC modes (reversed-phase, normal-phase, ion-exchange, size-exclusion) handle different kinds of separations, so you've got to pick the one that fits your needs. In pharmaceuticals, HPLC is fundamental for drug development, quality control, and pharmacokinetic studies. Environmental scientists use it to track pollutants, while clinicians rely on it for biomarker identification. All in all, HPLC is the go-to tool for isolating and purifying target compounds in a ton of scientific field.[60-65]

In the realm of downstream process development, hydrophobic interaction chromatography has emerged as a valuable technique, offering an orthogonal approach to conventional chromatography principles.[66] Chromatography is employed not only for separating substances but also as a means of quantitatively analyzing them, ensuring a satisfactory separation is achieved within an appropriate timeframe.[63] The technique boasts high selectivity, separation efficiency and resolution.[33] Various parts of mixtures remain in the stationary phase for an extended period due to their unique characteristics, causing them to progress slowly through the chromatography system, whereas some elements quickly transition to the mobile phase and exit the system promptly. [63]

IMPURITY PROFILING OF EFAVIRENZ:

Types of impurities: Efavirenz, a vital element in the therapy for HIV type 1 infection, acts as a non-nucleoside reverse transcriptase inhibitor. Its efficacy in reducing viral load and improving patient outcomes has made it a cornerstone of antiretroviral therapy.[13,14] The existence of impurities in efavirenz medication creates worries regarding its safety, effectiveness, and overall quality, calling for a comprehensive examination into where they come from and their potential consequences. Contaminants in medications like efavirenz aren't just undesirable—they can seriously compromise both the drug's efficacy and patient safety. Impurities can enter the mix during synthesis, from subpar raw materials, or even as the drug degrades over time due to environmental factors like light, heat, or humidity. This makes

rigorous quality control absolutely essential. Optimizing the synthesis process, controlling every reaction parameter, and sourcing only high-grade ingredients are all critical steps to limit impurity formation. At the same time, robust analytical methods are necessary to detect and quantify even trace contaminants, in line with regulatory standards. Failure to identify and control impurities can lead to toxic, carcinogenic, or teratogenic effects, making vigilant monitoring and control measures not just advisable, but essential for ensuring both drug safety and effectiveness.[1,6,67,68]

Efavirenz, like many organic molecules, is susceptible to degradation over time, leading to the formation of new chemical entities that may compromise the drug's quality and safety.[69] Stress testing, a process that involves exposing the drug substance to various environmental conditions, helps identify potential degradation pathways and products.[2] Understanding these pathways is essential for developing appropriate storage conditions, packaging, and formulations that minimize degradation. Forced degradation investigations are commonly utilized to assess chemical stability, degradation pathways, detection of degradation byproducts, storage conditions, shelf life, compatibility with excipients, and aid in product development.[70] and validation of stability indicating analytical procedures.[71] Some software and databases can predict how a pharmaceutically active substance will react when exposed to deterioration, which can be helpful in determining the main pathways of deterioration and the main resulting products of deterioration that occur during the storage of pharmaceutical products.[69]

Contaminants are a different type of impurities that may enter the product during the manufacturing process or from exposure to the environment. These can include inorganic salts, heavy metals, residual solvents, particulate matter, or microbial contaminants. Ensuring the quality of water used in pharmaceutical manufacturing is critical, as water can be a major source of contamination. Microbial contamination is especially problematic in non-sterile products, where microorganisms can proliferate and potentially cause harm to patients.[72]

Pharmaceutical companies can't afford to cut corners when it comes to quality control—it's absolutely crucial. They need to monitor everything closely, from the raw materials they use to the way the drugs are manufactured and stored. Contaminants can sneak in at any point, whether it's from the ingredients themselves, the equipment, or even lapses in cleanliness. That's why rigorous cleaning procedures are a must; any leftover residues or microbes could pose serious risks. Ultimately, keeping impurities in check is essential not just for patient safety, but also to ensure the medications actually work as intended and to maintain public health.[72-74]:

LCMS in impurity profiling: When it comes to analyzing Efavirenz, a critical medication in HIV therapy, monitoring impurities is non-negotiable. Impurities, whether they emerge during synthesis, formulation, or storage, can jeopardize drug safety and efficacy. Here's where LCMS (liquid chromatography-mass spectrometry) becomes indispensable. This technique is renowned for its sensitivity and specificity, making it a cornerstone in pharmaceutical analysis for tracing even minute contaminants. The analytical workflow typically includes careful sample preparation—often involving liquid-liquid or solid-phase extraction methods—to isolate Efavirenz and any associated impurities. Chromatographic separation follows, generally using reversed-phase columns, which leverage a hydrophobic stationary phase and a polar mobile phase gradient. Researchers meticulously adjust column selection, mobile phase composition, flow rate, and temperature to achieve optimal separation and resolution of analytes. LCMS does more than just detect impurities; it also provides essential insights into their structural characteristics and potential sources. Such information is vital for refining production processes and ensuring the ongoing quality and safety of pharmaceutical products. In summary, LCMS stands as a robust and versatile tool in the pharmaceutical field, crucial for maintaining the high standards required for drugs like Efavirenz.[6,24,35,67]

Mass spectrometry serves as a critical tool for identifying and quantifying compounds by sorting them according to their mass-to-charge ratios. In pharmaceutical analysis—Efavirenz and its impurities included—electrospray ionization and atmospheric pressure chemical ionization are widely employed. These ionization methods are particularly effective at producing ions from the analytes, enabling precise detection and measurement. Once ionized, the mass analyzer separates the ions based on their mass-to-charge ratios. The resulting mass spectra provide detailed information about the molecular weights and,

often, structural characteristics of the compounds. For enhanced sensitivity and selectivity, tandem mass spectrometry (MS/MS) is often utilized. This technique fragments precursor ions, and the analysis of the resulting product ions yields deeper insights, allowing for more accurate identification and quantification of the substances present.[75]

Mass fragmentation establishes the compound's molecular weight. Accurate mass measurements from high-resolution mass spectrometry, like time-of-flight mass spectrometry, can determine the elemental composition of compounds.[28]

Liquid chromatography, when used in conjunction with mass spectrometry and tandem mass spectrometry, has emerged as a valuable tool for detecting and analyzing psychoactive substances, as well as their byproducts, metabolites, and impurities formed during the manufacturing process.[23]

Data analysis includes analyzing mass spectral data to determine and measure impurities that have been detected. By combining high performance liquid chromatography and mass spectrometry with a hyphen, these rigorous requirements are met, offering the user a variety of technical possibilities and uses.[25] The acquired data is compared with reference standards or library data to confirm the identity of known impurities. Quantitative analysis is performed by constructing calibration curves using authentic standards of the target impurities. The level of impurities in the sample is established by comparing the peak areas or peak heights of the impurities with those of the standards. Also programs and expectation frameworks help in recognizing and deciding the structure of obscure compounds.[76]

1H NMR Analysis for Structural Elucidation of Impurities in Efavirenz: Identifying impurities in pharmaceuticals is crucial for ensuring drug safety and effectiveness. Advanced analytical methods like nuclear magnetic resonance (NMR) spectroscopy are essential for determining chemical structures. 1H NMR spectroscopy provides detailed information on hydrogen atoms in a molecule, helping identify unknown impurities in drugs like efavirenz. Analysis of 1H NMR spectra involves parameters like chemical shifts, signal intensities, splitting patterns, and coupling constants. Chemical shifts are sensitive to electronic environments, while signal strength depends on proton quantity. Signal splitting occurs due to interactions with neighboring protons, forming multiplets like singlets, doublets, and triplets. This information helps determine the structure of impurities[6,77].

The coupling constant, represented by 'J', is the gap between the peaks in a multiplet, measured in Hertz. It gives details about the dihedral angle between the connected protons, which helps in figuring out the three- dimensional shape of the molecule. The application of computer-assisted structure elucidation software packages can significantly aid in the interpretation of complex NMR spectra, especially when dealing with large and complex organic molecules.[39] Modern NMR machines are now smaller and more portable, allowing for the use of desktop and handheld devices to handle complex tasks like analyzing the structures of large molecules and performing industrial, environmental, and food testing on solids, liquids, and dispersed materials.[38]

Analyzing the 1H NMR spectrum of efavirenz and its associated impurities involves a systematic approach, starting with the identification of the known signals corresponding to the efavirenz molecule itself, using reference spectra and literature data. Any additional signals observed in the spectrum that do not correspond to efavirenz are indicative of impurities, which then need to be characterized.[43] The chemical shifts of these impurity signals can provide initial clues about the types of functional groups present, such as aromatic rings, alkyl chains, or heteroatoms. Signals between 7-8 ppm usually indicate aromatic protons, whereas signals between 0-2 ppm are usual for aliphatic protons. The integration of the impurity signals, relative to the efavirenz signals, allows for the quantitative determination of the amount of each impurity present in the sample. Multiplicity patterns, such as singlets, doublets, triplets, and quartets, provide valuable information about the connectivity of protons within the impurity molecule. Additionally, techniques like COSY and HSQC can be employed to establish connectivity between protons and carbon atoms, respectively, providing further structural information. By systematically analyzing these parameters, it is possible to piece together the structure of the unknown impurities and identify their origin, whether from synthetic byproducts, degradation products, or contaminants. The process becomes challenging and time-consuming because no method reports a complete analysis of total compounds.[78]

Nuclear magnetic resonance spectroscopy is capable of determining the location of functional groups like methyl groups or halogens on an aromatic ring.[49] Monoterpenes, for example, exhibit diastereotopic hydrogens and methyl groups that are readily identified using 13C-NMR and HETCOR techniques.[46] The use of 1H NMR spectroscopy in impurity profiling is particularly valuable in the pharmaceutical industry, where stringent regulations require the identification and quantification of all impurities present above a certain threshold. Developing and manufacturing pharmaceutical agents such as efavirenz requires a thorough understanding of both synthetic processes and the potential degradation pathways over time. This knowledge is fundamental in anticipating impurity formation within the final product. Impurities may result from incomplete reactions, or from exposure to environmental factors such as heat, light, or humidity. To safeguard both the quality and safety of the drug, it is imperative to identify and characterize these impurities. Analytical methods—including 1H NMR spectroscopy—are routinely employed to analyze various production batches of efavirenz. By evaluating and comparing these spectra, researchers can detect anomalies in impurity profiles, subsequently tracing them to specific alterations in manufacturing protocols or storage conditions. The identification and quantification of impurities are critical, as even trace levels can compromise both efficacy and safety. Beyond 1H NMR, scientists leverage additional techniques such as LC-MS and IR spectroscopy to achieve a comprehensive impurity profile. For example, IR spectroscopy aids in identifying functional groups, while mass spectrometry provides molecular weight data, facilitating a more detailed structural elucidation of unknown components. By integrating these complementary spectroscopic and chromatographic methods, researchers can fully characterize impurity structures, thereby maintaining rigorous quality standards. This multi-faceted approach not only protects public health but also ensures the reliability and therapeutic effectiveness of efavirenz and similar pharmaceuticals. Understanding and controlling impurity profiles is a cornerstone of pharmaceutical development and regulatory compliance.[1,2,68,79]

High-Performance Liquid Chromatography (HPLC) in efavirenz impurity profiling: stands as a fundamental tool in pharmaceutical analysis, particularly for the identification and quantification of impurities in drugs such as efavirenz. The necessity of impurity profiling cannot be overstated; even minimal levels of contaminants—whether originating from starting materials, degradation, or manufacturing processes—pose significant concerns for patient safety, especially considering the long-term administration of efavirenz in vulnerable populations. HPLC's underlying mechanism relies on the separation of components through their interactions with both the stationary and mobile phases. This selectivity allows for effective resolution of complex mixtures. In the case of efavirenz, method development involves meticulous optimization of parameters such as stationary phase selection, mobile phase composition, flow rate, and detection wavelength. Ultraviolet detection at 280 nm is commonly employed, as it provides sufficient sensitivity for the analytes of interest. The reversed-phase mode is particularly advantageous for isolating impurities in efavirenz preparations. Advancements such as Ultra-Performance Liquid Chromatography (UPLC) offer further benefits, including reduced analysis times and enhanced resolution, thereby improving the efficiency and reliability of impurity detection. These chromatographic techniques are not only applicable to efavirenz but are also widely used to monitor process-related impurities in various other pharmaceutical compounds, including agents like ezetimibe.[80-82]

In the pharmaceutical sector, there's an unmistakable push toward greater speed and efficiency in analytical methods. Sub-2 micron particle columns used in UHPLC have become key players here, enabling separations under extremely high pressures. The outcome? Sharper resolution and heightened sensitivity—attributes that are frankly indispensable when precision matters. Nano-liquid chromatography and capillary electrochromatography also deserve a nod, offering impressive selectivity and separation efficiency. Plus, they manage to deliver rapid analyses while keeping solvent consumption to a minimum. Altogether, these advances are reshaping how analytical challenges are tackled in the industry.[33] Hyphenated techniques, such as LC-MS and LC-MS/MS, provide enhanced selectivity and sensitivity for impurity detection and identification. LC-MS/MS has become the method of choice in recent years. Mass spectrometry detection allows for the determination of the molecular weight of separated compounds, aiding in the identification of unknown impurities. The advancement of automated techniques for extracting and purifying

samples helps minimize the need for manual handling, variability, and overall analysis time. Connecting on-line solid-phase extraction with HPLC or UHPLC techniques proves advantageous.[29] These advancements contribute to more robust and reliable impurity profiling of efavirenz, ultimately ensuring drug product quality and patient safety.

CHALLENGES AND FUTURE DIRECTION

Navigating the Complexities of Impurity Profiling- Challenges and Considerations: Impurity profiling is crucial for ensuring pharmaceutical safety and efficacy. It involves method development, validation, and adherence to regulatory requirements. Impurities can compromise therapeutic effects and pose health risks, necessitating careful monitoring and control. Impurities can originate from production materials, manufacturing processes, or storage changes. Robust analytical methods are needed to detect, quantify, and identify impurities. Sample preparation techniques like extraction and filtration are essential for isolating impurities. Method validation ensures accuracy and reliability of impurity profiling data. Regulatory guidelines, such as ICH, govern acceptable impurity levels in pharmaceuticals. Obtaining reference standards for impurities can be challenging, requiring expertise in synthetic chemistry. Mutagenic impurities require special attention due to their potential to cause DNA damage. Advanced analytical techniques like liquid chromatography-tandem mass spectrometry are necessary to detect and manage these impurities. Impurity profiling is a critical element in pharmaceutical development and quality control, ensuring medication safety and effectiveness. Thorough toxicological evaluation is essential to determine permissible levels of degradation products. Impurities can be identified or unidentified, intrinsic or extrinsic, and must be carefully controlled to minimize health risks.[2,5,7]

Emerging Techniques and Technologies for Impurity Profiling: Pharmaceutical analysis is undergoing a significant transformation with innovative techniques and technologies. Impurity profiling is crucial for ensuring drug quality and safety. Traditional methods have limitations, but advanced approaches like capillary electrophoresis and mass spectrometry are revolutionizing the field. Ultra-high-performance liquid chromatography enables precise and fast separations, while high-resolution mass spectrometry provides detailed structural data. Raman spectroscopy identifies polymorphs, hydrates, and salts. Chemometrics and data analytics tools streamline complex data analysis. Liquid chromatography purifies therapeutic drugs on a large scale. Laser-induced fluorescence is a sensitive method for qualitative and quantitative analysis. Advanced separation methods combined with mass spectrometry provide unparalleled capabilities for impurity profiling. These techniques guarantee the safety and effectiveness of pharmaceutical products. Chromatography plays a crucial role in separating, identifying, and purifying mixture components.Affinity chromatography separates proteins through non- covalent interactions with specific ligands. These advancements enhance pharmaceutical quality and Safety[7,26,29,76].

Conclusion: Impurity profiling is very important in making medicines, especially when it comes to ensuring that drugs are safe and of good quality. It helps find and understand any unwanted substances that may appear during the making,storing,or mixing of a drug. IN the case of efavirenz, Which is a key medicine used to treat HIV-1, using advanced techniques like HPLC, LC-MS, and NMR helps identify and measure impurities accurately. HPLC is used to separate complex mixtures and is important for checking and measuring impurities in the raw drug material and final product. LC-MS helps by combiningseperation with a sensitive method for detecting substances based on their mass,which allows for finding , understanding the structure of,and measuring even very small amount of impurities and breakdown products. NMR provides a clear way to determine the structure of impurities, making it possible to identify and measure them even when they are present in very small amounts. Using these methods together helps follow strict rules set by regulators, makes the quality check process more efficient, and helps avoid harmful effects, improve health results, and make manufacturing more effective. Using these different techniques for checking impurities in efavirenz shows a high level of accuracy in testing, supports safe medicines practices, and helps meet regulatory requirements. This combined method represents the future of controlling impurities in complex medicines, helping to make safe and high-quality drugs available worldwide.

The Role of LCMS, 1H NMR, and HPLC in Impurity Profiling: A Case Study of Efavirenz:

The functions, workings, and benefits of LC-MS, 1H NMR, and HPLC in impurity profiling for pharmaceutical analysis are succinctly compared in Table 1 below, with an emphasis on Efavirenz medication items.[92-98]

Techniques	**Main role in impurity profiling**	**Mechanism of action**	**Advantages**	**Application i Efavirenz analysis r**
LC-MS	Detection,identification and quantification of impurities	Seperates compounds by liquid chromatography; identifies by mass to charge ratio via mass spectrometry	High sensitivity and selectivity; able to specify and measure unknown impurities; suited to toxicological levels.	Detects quantifies a impurities, analyzes r fragmentation d patterns structural identification. f c r
1H-NMR	Structural elucidation of impurities	Analyzes hydrogen environments via magnetic resonance, giving chemical shift, splitting, and integration patterns.	Non-invasive, provides detailed structural and compositional information; reveals functional groups and connectivity.	Offers structural information for impurities detected in Efavirenz sample.
HPLC	Separation and of quantification impurities	Seperates analytes based on Stationary and mobile phase Interaction with various detectors (e.g.UV, lurescence)	High resolution; Quantitative; Adaptable with different detectors and radient/Chiral techniques.	Seperates uantifies a efavirenzmpurities, r ensuring regulatory d compliances.

Table 1: Analytical techniques comparison table

REFERENCE

1. Thakur, P. (2020) "isolation of pharmaceutical impurities from bulk drug preparations," International Journal of Advanced Research, 8(6), p. 1436. doi:10.21474/ijar01/11232.
2. Dhangar, K. et al. (2017) "impurity profiling of drugs towards safety and efficacy: theory and practice," Journal of the Chilean Chemical Society, 62(2), p. 3543. doi:10.4067/s0717- 97072017000200024.
3. Mammone, F.R. et al. (2023) "A Novel Validated UHPLC Method for the Estimation of Rosuvastatin and Its Complete Impurity Profile in Tablet Formulations," Molecules, 28(1), p. 431. doi:10.3390/molecules28010431.
4. Snodin, D.J. and McCrossen, S. (2012) "Guidelines and pharmacopoeial standards for pharmaceutical impurities: Overview and critical assessment," Regulatory Toxicology and Pharmacology. Elsevier BV, p. 298. doi:10.1016/j.yrtph.2012.03.016.
5. Parmar, I., Rathod, H.K.K. and Shaik, S. (2021) "A Review: Recent Trends in Analytical Techniques for Characterization and Structure Elucidation of Impurities in the Drug Substances," Indian Journal of Pharmaceutical Sciences, 83(3). doi:10.36468/pharmaceutical-sciences.789.
6. Qiu, F. et al. (2009) "Identification of a process impurity formed during synthesis of a nevirapine analogue HIV NNRT inhibitor using LC/MS and forced degradation studies," Journal of Pharmaceutical and Biomedical Analysis, 49(3), p. 733. doi:10.1016/j.jpba.2009.01.010.
7. Victoria, F. (2014) "Various Aspects in the Impurity Profiling of Pharmaceutical Formulations," Pharmaceutica Analytica Acta, 5(8). doi:10.4172/2153-2435.1000e163.
8. Charoo, N.A. et al. (2019) "Lesson Learnt from Recall of Valsartan and Other Angiotensin II Receptor Blocker Drugs Containing NDMA and NDEA Impurities," AAPS PharmSciTech, 20(5). doi:10.1208/s12249-019-1376-1.
9. Abdin, A.Y., Yeboah, P. and Jacob, C. (2020) "Chemical Impurities: An Epistemological Riddle with Serious Side Effects," International Journal of Environmental Research and Public Health. Multidisciplinary Digital Publishing Institute, p. 1030. doi:10.3390/ijerph17031030.
10. Szücs, R. et al. (2017) "Liquid chromatography in the pharmaceutical industry," in Elsevier eBooks. Elsevier BV, p. 515. doi:10.1016/b978-0-12-805392-8.00017-7.
11. Nordström, F.L. et al. (2023) "Prevalence of Impurity Retention Mechanisms in Pharmaceutical Crystallizations," Organic Process Research & Development, 27(4), p. 723. doi:10.1021/acs.oprd.3c00009.
12. Pathy, K. (2018) "Considerations for Successful Scale-Up to Tox Batches and Phase-Api (Bulk Drug substance)," Biomedical Journal of Scientific & Technical Research, 8(3). doi:10.26717/bjstr.2018.08.001662.
13. Castelnuovo, B. et al. (2016) "First-line antiretroviral therapy durability in a 10-year cohort of naïve adults started on treatment in Uganda," Journal of the International AIDS Society, 19(1). doi:10.7448/ias.19.1.20773.
14. Staszewski, S. et al. (1999) "Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults," New England Journal of Medicine, 341(25), p. 1865. doi:10.1056/nejm199912163412501.
15. Weber, I.T., Wang, Y. and Harrison, R.W. (2021) "HIV Protease: Historical Perspective and Current Research," Viruses. Multidisciplinary Digital Publishing Institute, p. 839. doi:10.3390/v13050839.
16. Doxey, C.H. (2021) "Receiving." doi:10.1002/9781119700548.ch10.
17. Gregson, J. et al. (2016) "Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study," The Lancet Infectious Diseases, 16(5), p. 565. doi:10.1016/s1473-3099(15)00536-8.
18. Atta, M.G., Seigneux, S. de and Lucas, G.M. (2018) "Clinical Pharmacology in HIV Therapy," Clinical Journal of the American Society of Nephrology. Lippincott Williams & Wilkins, p. 435. doi:10.2215/cjn.02240218.
19. Kalapila, A.G. and Marrazzo, J. (2016) "Antiretroviral Therapy for Prevention of Human Immunodeficiency Virus Infection," Medical Clinics of North America. Elsevier BV, p. 927. doi:10.1016/j.mcna.2016.03.013.
20. López-Cortés, L.F. et al. (2002) "Pharmacokinetic Interactions Between Efavirenz and Rifampicin in HIV-Infected Patients with Tuberculosis," Clinical Pharmacokinetics, 41(9), p. 681. doi:10.2165/00003088-200241090-00004.
21. Kuwahara, T., Yoshino, M. and Shirasaka, T. (2007) "Adverse Effects of Antiretroviral Agents," The Journal of AIDS Research, 9(3), p. 191. doi:10.11391/aidsr1999.9.191.
22. Narayanam, M. et al. (2013) "Critical practical aspects in the application of liquid chromatography– mass spectrometric studies for the characterization of impurities and degradation products," Journal of Pharmaceutical and Biomedical Analysis. Elsevier BV, p. 191. doi:10.1016/j.jpba.2013.04.027.
23. Bulska, E. et al. (2020) "Comprehensive Protocol for the Identification and Characterization of New Psychoactive Substances in the Service of Law Enforcement Agencies," Frontiers in Chemistry, 8. doi:10.3389/fchem.2020.00693.
24. Li, B. et al. (2009) "Characterization of impurities in tobramycin by liquid chromatography–mass spectrometry," Journal of Chromatography A, 1216(18), p. 3941. doi:10.1016/j.chroma.2009.03.023.
25. Steinmann, D. and Ganzera, M. (2010) "Recent advances on HPLC/MS in medicinal plant analysis," Journal of Pharmaceutical and Biomedical Analysis, 55(4), p. 744. doi:10.1016/j.jpba.2010.11.015.
26. Yao, S. et al. (2010) "Ten Years of Research into Phytomedicines Analysis - An Era in New Technologies and Methods," Current

Pharmaceutical Analysis, 6(4), p. 269. doi:10.2174/157341210793292383

27. Ashraf, S.A. et al. (2020) "UPLC-MS: An Emerging Novel Technology and Its Application in Food Safety," in IntechOpen eBooks. IntechOpen. doi:10.5772/intechopen.92455
28. Mattarozzi, M. and Careri, M. (2015) "Liquid Chromatography/Mass Spectrometry in Environmental Chemistry. doi:10.1002/9780470027318.a0840.pub2.
29. Núñez, Ó. et al. (2013) "State-of-the-art in fast liquid chromatography–mass spectrometry for bio- analytical applications," Journal of Chromatography B. Elsevier BV, p. 3. doi:10.1016/j.jchromb.2012.12.031.
30. Vázquez-Martínez, J. and López, M.G. (2019) "Chemometrics-Based TLC and GC-MS for Small Molecule Analysis: A Practical Guide," in IntechOpen eBooks. IntechOpen. doi:10.5772/intechopen.77160.
31. Václavík, L. et al. (2014) "Survey of Mass Spectrometry-Based High-Throughput Methods in Food Analysis." doi:10.1002/9781118907924.ch02.
32. Patil, A. et al. (2012) "Highly Sensitive High Performance Liquid Chromatography-Laser Induced Fluorescence for Proteomics Applications," ISRN Spectroscopy, 2012, p. 1. doi:10.5402/2012/643979.
33. Fanali, S. (2017) "An overview to nano-scale analytical techniques: Nano-liquid chromatography and capillary electrochromatography," Electrophoresis. Wiley, p. 1822. doi:10.1002/elps.201600573.
34. Bélanger, J.M.R., Paré, J.R.J. and Sigouin, M. (1997) "Chapter 2 High performance liquid chromatography (HPLC): Principles and applications," in Techniques and instrumentation in analytical chemistry. CRC Press, p. 37. doi:10.1016/s0167-9244(97)80011-x.
35. Holderied, I., Rychlik, M. and Elsinghorst, P.W. (2019) "Optimized Analysis of Ergot Alkaloids in Rye Products by Liquid Chromatography-Fluorescence Detection Applying Lysergic Acid Diethylamide as an Internal Standard," Toxins, 11(4), p. 184. doi:10.3390/toxins11040184.
36. Ridgway, K., Lalljie, S.P.D. and Smith, R.M. (2007) "Sample preparation techniques for the determination of trace residues and contaminants in foods," Journal of Chromatography A. Elsevier BV, p. 36. doi:10.1016/j.chroma.2007.01.134.
37. Cappiello, A. et al. (2008) "Overcoming Matrix Effects in Liquid Chromatography—Mass Spectrometry," Analytical Chemistry, 80(23), p. 9343. doi:10.1021/ac8018312.
38. Кужаева, А.А., Zgonnik, P.V. and Анисимова, Н.А. (2019) "Nuclear magnetic resonance methods – the key to determining the structure of organic substances," Journal of Physics Conference Series, 1384(1), p. 12071. doi:10.1088/1742-6596/1384/1/012071.
39. Soong, R. et al. (2020) "CASE (Computer-Assisted Structure Elucidation) Study for an Undergraduate Organic Chemistry Class," Journal of Chemical Education, 97(3), p. 855. doi:10.1021/acs.jchemed.9b00498.
40. Tampieri, A. et al. (2020) "A brief introduction to the basics of NMR spectroscopy and selected examples of its applications to materials characterization," Physical Sciences Reviews, 6(1). doi:10.1515/psr-2019-0086.
41. Grover, V.P.B. et al. (2015) "Magnetic Resonance Imaging: Principles and Techniques: Lessons for Clinicians," Journal of Clinical and Experimental Hepatology. Elsevier BV, p. 246. doi:10.1016/j.jceh.2015.08.001.
42. Arora, H. (2018) "Review of basic Concepts involved in Magnetic Resonance Imaging," Biomedical Journal of Scientific & Technical Research, 8(5). doi:10.26717/bjstr.2018.08.001726.
43. Emwas, A. et al. (2014) "Standardizing the experimental conditions for using urine in NMR-based metabolomic studies with a particular focus on diagnostic studies: a review," Metabolomics. Springer Science+Business Media, p. 872. doi:10.1007/s11306-014-0746-7.
44. Fulmer, G.R. et al. (2010) "NMR Chemical Shifts of Trace Impurities: Common Laboratory Solvents, Organics, and Gases in Deuterated Solvents Relevant to the Organometallic Chemist," Organometallics, 29(9), p. 2176. doi:10.1021/om100106e.
45. Renner, G., Schmidt, T. and Schram, J. (2016) "Characterization and Quantification of Microplastics by Infrared Spectroscopy," in Comprehensive analytical chemistry. Elsevier BV, p.
67. doi:10.1016/bs.coac.2016.10.006.
46. Alty, L.T. (2005) "Monoterpene Unknowns Identified Using IR, 1H-NMR, 13C-NMR, DEPT, COSY, and HETCOR," Journal of Chemical Education, 82(9), p. 1387. doi:10.1021/ed082p1387.
47. Booker, A. et al. (2016) "From Traditional Resource to Global Commodities:—A Comparison of Rhodiola Species Using NMR Spectroscopy—Metabolomics and HPTLC," Frontiers in Pharmacology, 7. doi:10.3389/fphar.2016.00254.
48. Peterson, D.J. and Loening, N.M. (2007) "QQ-HSQC: a quick, quantitative heteronuclear correlation experiment for NMR spectroscopy," Magnetic Resonance in Chemistry, 45(11), p. 937. doi:10.1002/mrc.2073.
49. Duffy, J. et al. (2018) "Differentiation of fentanyl analogues by low-field NMR spectroscopy," Analytica Chimica Acta, 1049, p. 161. doi:10.1016/j.aca.2018.12.014.
50. Hu, J.Z., Xiao, X. and Hu, M.Y. (2016) "NMR Metabolomics in Ionizing Radiation.," PubMed, 1. Available at: https://pubmed.ncbi.nlm.nih.gov/28707005 (Accessed: February 2025).
51. Huck, C.W. (2015) "Infrared Spectroscopic Technologies for the Quality Control of Herbal Medicines," in Elsevier eBooks. Elsevier BV, p. 477. doi:10.1016/b978-0-12-800874-4.00022-2.
52. Wen, Q. et al. (2023) "Production Technology and Functionality of Bioactive Peptides," Current Pharmaceutical Design. Bentham Science Publishers, p. 652. doi:10.2174/1381612829666230201121353.
53. Boiteau, R. et al. (2018) "Structure Elucidation of Unknown Metabolites in Metabolomics by Combined NMR and MS/MS Prediction," Metabolites, 8(1), p. 8. doi:10.3390/metabo8010008.

54. McLafferty, F.W. (2008) "Mass spectrometry across the sciences," Proceedings of the National Academy of Sciences, 105(47), p. 18088. doi:10.1073/pnas.0800784105.
55. Reuhs, B.L. and Rounds, M.A. (2010) "High-Performance Liquid Chromatography," in Food science text series. Springer Nature, p. 499. doi:10.1007/978-1-4419-1478-1_28.
56. Galant, A., Kaufman, R.C. and Wilson, J.D. (2015) "Glucose: Detection and analysis," Food Chemistry. Elsevier BV, p. 149. doi:10.1016/j.foodchem.2015.04.071.
57. Shi, Y. et al. (2022) "Recent Progress in the Study of Taste Characteristics and the Nutrition and Health Properties of Organic Acids in Foods," Foods. Multidisciplinary Digital Publishing Institute,
p. 3408. doi:10.3390/foods11213408.
58. Wu, N. and Thompson, R.A. (2006) "Fast and Efficient Separations Using Reversed Phase Liquid Chromatography," Journal of Liquid Chromatography &amp Related Technologies, 29, p. 949. doi:10.1080/10826070600574903.
59. Croley, T.R. (2010) "Ultra-Performance Liquid Chromatography–Mass Spectrometry of Proteins," Methods in molecular biology, p. 419. doi:10.1007/978-1-60761-913-0_23.
60. Caleb, J. et al. (2020) "Dispersive liquid-liquid microextraction for the isolation and HPLC-DAD determination of three major capsaicinoids in Capsicum annuum L.," TURKISH JOURNAL OF CHEMISTRY [Preprint]. doi:10.3906/kim-2009-55
61. Snyder, L.R., Kirkland, J.J. and Glajch, J.L. (1997) Practical HPLC Method Development. doi:10.1002/9781118592014.
62. Boysen, R.I. and Hearn, M.T.W. (2010) "High Performance Liquid Chromatographic Separation Methods," in Elsevier eBooks. Elsevier BV, p. 5. doi:10.1016/b978-008045382-8.00183-0.
63. Coşkun, Ö. (2016) "Separation Tecniques: CHROMATOGRAPHY," Northern Clinics of Istanbul. KARE Publishing. doi:10.14744/nci.2016.32757.
64. Goswami, J. (2015) "Different Separation or Experimental Techniques for Clinical Chromatography: Small Review," Journal of Chromatography & Separation Techniques, 6(7). doi:10.4172/2157-7064.1000297.
65. Poole, C.F. (2003) "Laboratory-Scale Preparative Chromatography," in Elsevier eBooks. Elsevier BV, p. 847. doi:10.1016/b978-044450198-1/50024-0.
66. Graumann, K. and Ebenbichler, A.A. (2005) "Development and Scale up of Preparative HIC for the Purification of a Recombinant Therapeutic Protein," Chemical Engineering & Technology, 28(11),
p. 1398. doi:10.1002/ceat.200500165.
67. Raman, B. et al. (2009) "Structural elucidation of a process-related impurity in ezetimibe by LC/MS/MS and NMR," Journal of Pharmaceutical and Biomedical Analysis, 52(1), p. 73. doi:10.1016/j.jpba.2009.12.021.
68. Guntupalli, S. et al. (2013) "Identification, isolation and characterization of process related impurities in ezetimibe," Journal of Pharmaceutical and Biomedical Analysis, 88, p. 385. doi:10.1016/j.jpba.2013.09.020.
69. Melo, S.R. de et al. (2014) "Advice on Degradation Products in Pharmaceuticals: A Toxicological Evaluation," PDA Journal of Pharmaceutical Science and Technology. Parenteral Drug Association,
p. 221. doi:10.5731/pdajpst.2014.00974.
70. Alvarenga, B.R. de and Carneiro, R.L. (2019) "Chemometrics Approaches in Forced Degradation Studies of Pharmaceutical Drugs," Molecules. Multidisciplinary Digital Publishing Institute, p. 3804. doi:10.3390/molecules24203804.
71. Singh, S. et al. (2013) "Forced degradation studies to assess the stability of drugs and products," TrAC Trends in Analytical Chemistry, 49, p. 71. doi:10.1016/j.trac.2013.05.006.
72. Murtaza, G. et al. (2021) "A Review on the Microbial Contamination in the Non-sterile Pharmaceutical Products," Pharmaceutical Science and Technology. Science Publishing Group, p.
68. doi:10.11648/j.pst.20210502.17.
73. Prabu, S.L., Prakash, T.N.K.S. and Thirumurugan, R. (2014) "Cleaning Validation and Its Regulatory Aspects in the Pharmaceutical Industry," in Elsevier eBooks. Elsevier BV, p. 129. doi:10.1016/b978-0-323-31303-2.00005-4.
74. athore, N. and Rajan, R.S. (2008) "Current Perspectives on Stability of Protein Drug Products during Formulation, Fill and Finish Operations," Biotechnology Progress. American Chemical Society, p. 504. doi:10.1021/bp070462h.
75. Ladwig, P.M., Barnidge, D.R. and Willrich, M.A.V. (2017) "Mass Spectrometry Approaches for Identification and Quantitation of Therapeutic Monoclonal Antibodies in the Clinical Laboratory," Clinical and Vaccine Immunology. American Society for Microbiology. doi:10.1128/cvi.00545-16.
76. Krauß, M., Singer, H. and Hollender, J. (2010) "LC–high resolution MS in environmental analysis: from target screening to the identification of unknowns," Analytical and Bioanalytical Chemistry, 397(3), p. 943. doi:10.1007/s00216-010-3608-9.
77. Valenzuela-Gloria, M.S. et al. (2021) "Molecular Characterization of Fungal Pigments," Journal of Fungi. Multidisciplinary Digital Publishing Institute, p. 326. doi:10.3390/jof7050326.
78. Ouyang, H. et al. (2016) "Identification and Quantification Analysis on the Chemical Constituents from Traditional Mongolian Medicine Flos Scabiosae Using UHPLC–DAD–Q-TOF-MS Combined with UHPLC–QqQ-MS," Journal of Chromatographic Science, 54(6), p. 1028. doi:10.1093/chromsci/bmw041.
79. Becht, A. et al. (2021) "Tracing the origin of paracetamol tablets by near-infrared, mid-infrared, and nuclear magnetic resonance spectroscopy using principal component analysis and linear discriminant analysis," Analytical and Bioanalytical Chemistry, 413(11), p. 3107. doi:10.1007/s00216-021-03249-z.

80. Zhao, M. et al. (2022) "Identification, synthesis and characterization of avanafil process impurities and determination by UPLC," RSC Advances, 12(15), p. 9256. doi:10.1039/d2ra01224c
81. Wu, S.S., Chein, C.-Y. and Wen, Y.-H. (2008) "Analysis of Ciprofloxacin by a Simple High- Performance Liquid Chromatography Method," Journal of Chromatographic Science, 46(6), p. 490. doi:10.1093/chromsci/46.6.490.
82. Liu, M. et al. (2007) "Extraction and ultra-performance liquid chromatography of hydrophilic and lipophilic bioactive components in a Chinese herb Radix Salviae Miltiorrhizae," Journal of Chromatography A, 1157, p. 51. doi:10.1016/j.chroma.2007.05.018.
83. Gorman, P.M. and Jiang, H. (2004) "Isolation methods I: Thin-layer chromatography," in Separation science and technology. Elsevier BV, p. 203. doi:10.1016/s0149-6395(03)80011-9.
84. Betz, J.M., Brown, P.N. and Roman, M. (2010) "Accuracy, precision, and reliability of chemical measurements in natural products research," Fitoterapia. Elsevier BV, p. 44. doi:10.1016/j.fitote.2010.09.011.
85. Singh, D.K. et al. (2018) "Pharmaceutical Analysis—Drug Purity Determination," in Elsevier eBooks. Elsevier BV. doi:10.1016/b978-0-12-409547-2.14551-2.
86. Madadlou, A., O'Sullivan, S. and Sheehan, D. (2010) "Fast Protein Liquid Chromatography," Methods in molecular biology, p. 439. doi:10.1007/978-1-60761-913-0_25.
87. Unger, K.K. et al. (2010) "Liquid Chromatography—Its Development and Key Role in Life Science Applications," Angewandte Chemie International Edition. Wiley, p. 2300. doi:10.1002/anie.200906976.
88. osen, R. (2007) "Mass spectrometry for monitoring micropollutants in water," Current Opinion in Biotechnology, 18(3), p. 246. doi:10.1016/j.copbio.2007.03.005.
89. Bhavyasri, K., Saileela, S. and Sumakanth, M. (2023) "high-resolution mass spectroscopy (HRMS)-a review," International Journal of Current Pharmaceutical Research, p. 9. doi:10.22159/ijcpr.2023v15i3.3008.
90. Sasidharan, S. et al. (2010) "Extraction, Isolation And Characterization Of Bioactive Compounds From Plants' Extracts," African Journal of Traditional Complementary and Alternative Medicines,
8(1). doi:10.4314/ajtcam.v8i1.60483.
91. Hage, D.S. (1999) "Affinity Chromatography: A Review of Clinical Applications," Clinical Chemistry. American Association for Clinical Chemistry, p. 593. doi:10.1093/clinchem/45.5.593.
92. Farouk, F., Moussa, B.A. and Azzazy, H.M.E. (2011) "Fourier transform infrared spectroscopy for in-process inspection, counterfeit detection and quality control of anti-diabetic drugs," Spectroscopy, 26, p. 297. doi:10.3233/spe-2011-0531.
93. Kim, E.J. et al. (2021) "Process Analytical Technology Tools for Monitoring Pharmaceutical Unit Operations: A Control Strategy for Continuous Process Verification," Pharmaceutics. Multidisciplinary Digital Publishing Institute, p. 919. doi:10.3390/pharmaceutics13060919.
94. Orlandini, S., Pinzauti, S. and Furlanetto, S. (2012) "Application of quality by design to the development of analytical separation methods," Analytical and Bioanalytical Chemistry, 405, p.
443. doi:10.1007/s00216-012-6302-2.
95. Xie, W. et al. (2019) "Interpretable Biomanufacturing Process Risk and Sensitivity Analyses for Quality-by-Design and Stability Control," arXiv (Cornell University) [Preprint]. doi:10.48550/arxiv.1909.04261.
96. Mohamed, M. et al. (2021) "Determination of microbial recovery for some pharmaceutical raw materials and passive monitoring at production area and microbiology laboratory at Egyptian pharmaceutical company," Journal of Advanced Pharmacy Research, p. 0. doi:10.21608/aprh.2021.72862.1127.
97. Prasad, S.K., Diwekar, K. and Anita.A (2020) "QBD, review on comprehensive understanding of building an analytical quality by design for drug manufacturing process," Journal of Biomedical and Pharmaceutical Research, 9(2). doi:10.32553/jbpr.v9i2.744.
98. Anderson, N.G. (2012) "Optimizing Processes by Minimizing Impurities," in Elsevier eBooks. Elsevier BV, p. 237. doi:10.1016/b978-0-12-386537-3.00009-5.